Three cases of acute venous thromboembolism in females after vaccination for coronavirus disease 2019.

Abstract

Since December 2020, four vaccines for SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) have been developed, and three have been approved for immediate use in the United States. Two are mRNA vaccines, and one uses a viral vector mechanism. Thrombotic complications have been reported after vaccine administration, which were primarily cerebral sinus thromboses after administration of the viral vector vaccines. To the best of our knowledge, we are the first to report venous thrombotic complications within days of administration of the mRNA-1273 (Moderna) vaccine. We present a series of three women who developed venous thromboembolism after RNA-1273 vaccination at a single healthcare system.

• Authors: Elizabeth A Andraska, Rohan Kulkarni, Mirnal Chaudhary, Ulka Sachdev
• Journal: Journal of vascular surgery. Venous and lymphatic disorders (J Vasc Surg Venous Lymphat Disord) Vol. 10 Issue 1 Pg. 14-17 (01 2022) ISSN: 2213-3348 [Electronic] United States
• PMID: 34352418 (Publication Type: Case Reports, Research Support, N.I.H., Extramural)
• Copyright: Copyright © 2021 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Chemical References

• 2019-nCoV Vaccine mRNA-1273

Topics

• 2019-nCoV Vaccine mRNA-1273 (adverse effects)
• Adult
• Aged
• Aged, 80 and over
• COVID-19 (prevention & control)
• Computed Tomography Angiography
• Female
• Humans
• SARS-CoV-2 (immunology)
• Ultrasonography, Doppler
• Vaccination (adverse effects)
• Venous Thromboembolism (chemically induced, diagnosis)